US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
We have updated Recombinant Vaccines Market with respect to COVID-19 Business Impact. Inquire before buying This report focuses on the Recombinant Vaccines market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Recombinant Vaccines market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.
Global Recombinant Vaccines Market: Segment AnalysisThe research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.
Global Recombinant Vaccines Market: Regional AnalysisThe research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.
Global Recombinant Vaccines Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies ProfiledGlaxoSmithKline plc and Merck & Co., Inc Lead the Market Owing To Effective Recombinant Vaccines The recombinant vaccines market is dominated by GlaxoSmithKline plc and Merck Co., Inc due to their strong vaccine portfolio and implementation of key distribution strategy in the developed as well as developing nations. GSK has a strong portfolio of recombinant vaccines against human papillomavirus, hepatitis B, rotavirus, and others. GSKs Shingrix vaccine indicated against herpes zoster is currently leading as the companys top-selling vaccine. Likewise, Merck Co., Inc also has an effective recombinant vaccine portfolio in competition to GSKs portfolio. The companys top-selling recombinant vaccines Gardasil and Gardasil 9 are contributing to the leading position of Merck. Moreover, the company is focused on launching novel vaccines in the market against complex viral diseases. Recently, Merck received USFDA approval for its Ervebo vaccine indicated against the ebola virus. Ervebo is also the worlds first ebola virus vaccine. The rising competitive tension between key players, coupled with challenges in launching effective recombinant vaccines, will boost the market players to introduce novel vaccines.
List of key Companies Covered:
- GlaxoSmithKline plc.
- Merck & Co., Inc
- Pfizer Inc
- Dynavax Technologies
- Serum Institute of India Pvt. Ltd
- Novartis AG
- Other Prominent Players
REPORT COVERAGEAn Infographic Representation of Recombinant Vaccines Market View Full Infographic To get information on various segments, share your queries with us Advances in the molecular biology, genomics, and proteomics techniques have added new perspective in the development of genetically modified vaccines against complex disorders. This advancement has helped scientists worldwide in putting strategic efforts in fighting viral diseases. Broad range of application in the field of recombinant DNA technology, coupled with increasing competition between key players to launch effective vaccines, is expected to drive the recombinant vaccines market during the forecast period. Along with this, the report provides a detailed analysis of the recombinant vaccines market and focuses on the key aspects such as leading companies, product types, and leading applications of the product. Besides, the report offers insights into the market trends and highlights key industry developments. In addition to the features above, the report encompasses several factors that have contributed to the growth of the market over the recent years. Furthermore, it offers a detailed analysis and information as per market segments, helping our readers to get a comprehensive overview of the global market.
Report Scope & Segmentation
- Live Attenuated
By Route of Administration
By Disease Indication
- Human Papillomavirus
- Hepatitis B
- Herpes Zoster
- Meningococcal B
By Distribution Channel
- Hospitals & Retail Pharmacies
- Government Suppliers
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
In August 2020,MYR GmbH received marketing authorization valid throughout the European Union for Hepcludex(Bulevirtide) which is an antiviral medicine used to treat chronic (long-term) hepatitis delta virus (HDV) infection in adults with compensated liver disease (when the liver is damaged but is still able to work), when the presence of viral RNA (genetic material) has been confirmed by blood tests. HDV is an 'incomplete' virus, because it cannot replicate in cells without the help of another virus, the hepatitis B virus. Because of this, patients infected with the virus always also have hepatitis B. Hepcludex can be given on its own, or in combination with a ‘nucleoside/nucleotide analogue’ medicine for the treatment of the underlying hepatitis B infection. The active substance in Hepcludex, bulevirtide, works by attaching to and blocking a receptor (target) through which the hepatitis delta and hepatitis B viruses enter liver cells. By blocking the entry of the virus into the cells, Hepcludex limits the ability of HDV to replicate and its effects in the body, reducing symptoms of the disease. HDV infection is rare, and Hepcludex was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 June 2015. MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D.
December 2019: Merck received USFDA green signal to launch the first Ebola vaccine ERVEBO. Ervebo is a recombinant viral vaccine indicated against zaire ebolavirus.
December 2018: Sanofi and MSD received USFDA approval for VAXELIS, a combination vaccine indicated against DTP, haemophilus B, and hepatitis B. Vaxelis is a recombinant vaccine for hepatitis B.
October 2017: USFDA approved GlaxoSmithKline new vaccine SHINGRIX indicated against herpes zoster.
Table of Content Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions 1.3. List of Data Sources Chapter 2. Executive Summary Chapter 3. Recombinant Vaccines Market 3.1. Market Segmentation 3.2. Market Size and Growth Prospects, 2019 - 2029 3.3. Value Chain Analysis 3.4. Market Dynamics 3.4.1. Market driver analysis 3.4.2. Market restraint analysis Chapter 4. Market Size by Application 4.1 Recombinant Vaccines Market Consumption by Application (2015-2020) 4.2 Recombinant Vaccines Market Consumption by Application (2020-2029) | read more...